Biotechnology
Wistar Institute Researchers Discover New Combination Therapy Approach for Metastatic Ovarian Cancer
Zhang Lab Demonstrates Novel Combination of Beta Glucan and Interferon Gamma Results in Tumor Regression Excerpt from the Press Release: PHILADELPHIA — (November 21, 2024) — The Wistar Institute’s Nan Zhang, Ph.D., assistant professor in the Ellen and Ronald Caplan Cancer Center’s Molecular and Cellular Oncogenesis Program, and lab have discovered a new approach to treating ovarian…
Read More
Excerpt from the Press Release: PLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–HiFiBiO Therapeutics, a clinical stage biotechnology company focused on immune modulation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for HFB200604. HFB200604 is a best-in-class BTLA agonist monoclonal antibody, developed using HiFiBiO’s proprietary Drug Intelligence Science (DIS®) platform.…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., Oct. 28, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for…
Read More
Novel SEQ SIFTER™ discovery platform used to re-engineer original human IgE antibodies into IgG antibodies to block binding and protect against peanut allergen Topline data expected in mid-2025 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 /PRNewswire/ — IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune mediated diseases,…
Read More
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn’s selective SMARCA2 oncology program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Lilly Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) —…
Read More
Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ART5803. ART5803 is a therapeutic monoclonal antibody candidate designed to specifically compete with pathogenic autoantibodies targeting the NMDA…
Read More
New lab and scientific talent in Toronto to strengthen cell therapy developmentcapabilities in Canada Excerpt from the Press Release: TORONTO and SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ — cTRL Therapeutics, a biotechnology company advancing next-generation cell therapies for solid tumors, announced that it has secured a follow-on investment from FACIT, further enabling cTRL to build out…
Read More
The National Institute of Diabetes and Digestive and Kidney Diseases Awards Vaxess SBIR Phase I Funding to Test Company’s MIMIX Transdermal Patch Platform in Administering GLP-1 RA Therapies Excerpt from the Press Release: CAMBRIDGE, Mass., October 1, 2024 — Vaxess Technologies, Inc., a biotech company developing a novel transdermal patch technology to transform home delivery…
Read More
Sutter Hill Ventures-led round will accelerate drug pipeline development and advance commercialization efforts, bringing science a step closer to targeting aging Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced that it has…
Read More